Program
pyronaridine
Also written as “Pyronaridine”, “Pyronaridine Tetraphosphate” and “Pyronaridine 540 mg”.
Its studies are mostly in Malaria, Falciparum · Leukemia, Myeloid, Acute, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck KGaA, Darmstadt, Germany | 20 open or running | phase 2since Jan 9, 2023 | Jan 9, 2023 | none ahead |
| Armaceutica | 10 open or running | phase 2since Oct 7, 2021 | Oct 7, 2021 | none ahead |
| Merck | 11 open or running | phase 1since Oct 30, 2026 | Oct 30, 2026 | Apr 5, 2027phase 1 · NCT07919028 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 7, 2021First study: phase 2 study in Leukemia, Myeloid, AcuteNew to ArmaceuticaArmaceutica · NCT05291390 · 200 enrolled · Senegal
- Jan 9, 2023Merck KGaA, Darmstadt, Germany's first study: phase 2 study in Acute malariaNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT05689047 · 38 enrolled · Burkina Faso, Gabon, Mozambique and more
- Jul 25, 2023Phase 2 study in Malaria, FalciparumMerck KGaA, Darmstadt, Germany · NCT05974267 · 192 enrolled · Burkina Faso, Kenya, The Gambia and more
- Oct 30, 2026Merck's first study: phase 1 study in HealthyNew to MerckMerck · NCT07919028 · 24 planned
Ahead
- Apr 5, 2027Primary completion: phase 1 study in HealthyMerck · NCT07919028
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07919028Healthy | 1 | Not yet recruiting | Merck | Apr 5, 2027 | 24 |
| NCT05974267Malaria, Falciparum · Burkina Faso, Kenya, The Gambia and more | 2 | Completed | Merck KGaA, Darmstadt, Germany | Dec 29, 2024 | 192 |
| NCT05689047Acute malaria · Burkina Faso, Gabon, Mozambique and more | 2 | Completed | Merck KGaA, Darmstadt, Germany | May 28, 2024 | 38 |
| NCT05291390Leukemia, Myeloid, Acute · Senegal | 2 | Suspended | Armaceutica | Feb 2030 | 200 |
How it is read
Names in the registry
- “Pyronaridine”, 2 entries
- “Pyronaridine Tetraphosphate”, 1 entry
- “Pyronaridine 540 mg”, 1 entry
- “Pyronaridine 720 mg”, 1 entry
Conditions, from the studies’ own filings
- Malaria, Falciparum, 2 studies
- Leukemia, Myeloid, Acute, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.